Name | Number of supported studies | Average coverage | |
---|---|---|---|
macrophage | 25 studies | 31% ± 15% | |
classical monocyte | 20 studies | 29% ± 13% | |
non-classical monocyte | 20 studies | 35% ± 14% | |
mast cell | 14 studies | 26% ± 8% | |
monocyte | 10 studies | 29% ± 8% | |
conventional dendritic cell | 7 studies | 24% ± 7% | |
alveolar macrophage | 6 studies | 28% ± 6% | |
dendritic cell | 6 studies | 29% ± 12% | |
basal cell | 6 studies | 24% ± 8% | |
myeloid cell | 5 studies | 30% ± 5% | |
ciliated cell | 5 studies | 31% ± 3% | |
erythroblast | 4 studies | 38% ± 12% | |
fibroblast | 4 studies | 27% ± 11% | |
smooth muscle cell | 4 studies | 19% ± 2% | |
endothelial cell | 4 studies | 20% ± 3% | |
erythrocyte | 4 studies | 32% ± 12% | |
epithelial cell | 3 studies | 34% ± 11% | |
tissue-resident macrophage | 3 studies | 21% ± 3% | |
intermediate monocyte | 3 studies | 39% ± 15% | |
type I pneumocyte | 3 studies | 28% ± 9% | |
GABAergic neuron | 3 studies | 24% ± 4% | |
glutamatergic neuron | 3 studies | 28% ± 8% | |
mononuclear phagocyte | 3 studies | 30% ± 11% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 100% | 1177.08 | 651 / 653 | 100% | 81.73 | 604 / 605 |
prostate | 100% | 1810.63 | 245 / 245 | 99% | 73.39 | 499 / 502 |
skin | 100% | 1470.78 | 1808 / 1809 | 99% | 92.71 | 469 / 472 |
breast | 100% | 2107.19 | 459 / 459 | 99% | 144.09 | 1107 / 1118 |
uterus | 100% | 1930.14 | 170 / 170 | 99% | 91.91 | 454 / 459 |
brain | 99% | 1147.76 | 2612 / 2642 | 100% | 87.82 | 704 / 705 |
kidney | 100% | 1661.06 | 89 / 89 | 98% | 101.02 | 885 / 901 |
lung | 100% | 2638.93 | 578 / 578 | 97% | 104.62 | 1120 / 1155 |
adrenal gland | 100% | 1228.87 | 258 / 258 | 97% | 67.38 | 223 / 230 |
ovary | 100% | 1998.99 | 180 / 180 | 96% | 46.02 | 413 / 430 |
pancreas | 94% | 596.45 | 307 / 328 | 97% | 65.38 | 173 / 178 |
esophagus | 100% | 2643.55 | 1445 / 1445 | 89% | 49.83 | 162 / 183 |
bladder | 100% | 1792.86 | 21 / 21 | 87% | 57.87 | 436 / 504 |
stomach | 99% | 1416.19 | 357 / 359 | 74% | 28.03 | 211 / 286 |
intestine | 98% | 2018.96 | 948 / 966 | 70% | 28.93 | 370 / 527 |
adipose | 100% | 2184.86 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 116.89 | 29 / 29 |
spleen | 100% | 3663.34 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 98.17 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 94.33 | 1 / 1 |
blood vessel | 100% | 2173.16 | 1334 / 1335 | 0% | 0 | 0 / 0 |
muscle | 100% | 1455.78 | 802 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 99% | 59.99 | 79 / 80 |
peripheral blood | 97% | 1567.12 | 903 / 929 | 0% | 0 | 0 / 0 |
heart | 96% | 1319.82 | 824 / 861 | 0% | 0 | 0 / 0 |
liver | 12% | 61.13 | 27 / 226 | 72% | 35.22 | 294 / 406 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0042167 | Biological process | heme catabolic process |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005829 | Cellular component | cytosol |
GO_0106277 | Molecular function | biliverdin reductase (NADP+) activity |
GO_0106276 | Molecular function | biliberdin reductase (NAD+) activity |
GO_0005515 | Molecular function | protein binding |
GO_0008270 | Molecular function | zinc ion binding |
GO_0000166 | Molecular function | nucleotide binding |
GO_0004074 | Molecular function | biliverdin reductase [NAD(P)+] activity |
Gene name | BLVRA |
Protein name | Biliverdin reductase A Biliverdin reductase A (BVR A) (EC 1.3.1.24) (Biliverdin-IX alpha-reductase) |
Synonyms | BVR BLVR |
Description | FUNCTION: Reduces the gamma-methene bridge of the open tetrapyrrole, biliverdin IX alpha, to bilirubin with the concomitant oxidation of a NADH or NADPH cofactor . Uses the reactants NADH or NADPH depending on the pH; NADH is used at the acidic pH range (6-6.9) and NADPH at the alkaline range (8.5-8.7) . NADPH, however, is the probable reactant in biological systems . . |
Accessions | ENST00000265523.9 C9J1E1 ENST00000424330.1 P53004 ENST00000402924.5 |